All In Biotech

Drug Trial Radar · NCT01310803

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER

Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1

Actual

Start

May 2011

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Sponsor type
Industry
First posted
Mar 9, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3b open-label, randomized, parallel-arm, multicenter study to evaluate the efficacy and safety of 10 monthly intravesical administrations of maintenance therapy with valrubicin following induction with valrubicin as compared to induction with valrubicin only in subjects with CIS of the bladder. The randomization will be 1:1 and subjects will be stratified by tumor type (CIS plus papillary disease vs. CIS only) and time from last bacillus Calmette-Guerin (BCG) failure (\>1 year vs. \<1 year).

Conditions

  • Carcinoma in Situ
  • Transitional Cell Carcinoma
  • Non-muscle Invasive Bladder Cancer

Interventions

  • VALSTAR - Maintenance TherapyDrug

    Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase

  • No Maintenance treatment ( Standard of Care)Other

    Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Evaluate the Efficacy of Maintenance Therapy With Valrubicin After Induction With Valrubicin, as Compared to Induction With Valrubicin Only in Subjects With CIS of the Bladder.Time frame: 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • BCG Oncology

    Phoenix, Arizona

  • The Urology Center of Colorado

    Denver, Colorado

  • Urology Associates

    Cumberland, Maryland

  • Delaware Valley Urology

    Sewell, New Jersey

  • Associated Medical Professionals of New York

    Syracuse, New York

  • Urologic Consultants of SE PA

    Bala-Cynwyd, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.